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Abstract
Background: The reconstitution of  cellular immune components contributes to clinical outcome of  HIV and Mycobacterium 
tuberculosis (MTB) infection. Interruption of  anti-retroviral therapy (ART) could lead to perturbations in reconstitution of  T cells 
in HIV/ tuberculosis (TB) patients.
Objectives: To ascertain the effect of  interrupted ART on reconstitution of  CD4+ and CD8+ T sub-sets in TB patients.
Methods: Participants with HIV (CD4>350 cells/µL) and TB were recruited under a larger phase 3 open label randomised 
controlled clinical trial. The CD45RO and CD62L markers were measured on CD4+ and CD8+ cells by flow cytometry. Samples 
were analysed at baseline, 3, 6, 12 months.
Results: There was a significant increase of  naive CD8+ cells (p = 0.003) and a decrease in effector CD8+ cells (p = 0.004) 
among participants in ART/TB treatment arm during the first 6 months. Withdrawing ART led to naive CD8+ cells reduction 
(p=0.02) to values close to baseline. An increase of  naive CD8+ cells after 6 months of  TB treatment in TB alone treatment arm 
(p=0.01) was observed. A trend towards increment of  naive CD4+ sub sets in either treatment arms was observed.
Conclusion: Interrupting ART alters CD8+ but not CD4+ sub-sets in patients with less advanced HIV infection and TB. 
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Introduction
One in every four of  human immunodeficiency virus 
type-1 (HIV-1) infected persons in the world is diagnosed 
with active pulmonary tuberculosis (TB)1.Tuberculosis 
accelerates progression of  HIV infection to acquired im-
mune deficiency syndrome (AIDS) compared to HIV pa-
tients without TB2,3. In Uganda at least 39% of  TB cases 
in adults are complicated with HIV infection which poses 
a risk of  high fatality rates4.
@ 2017 Nalukwago et al; licensee African Health Sciences. This is an Open Access article distributed under the termsof  the Creative commons Attribu-
tion License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided 
the original work is properly cited.  
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The HIV infection is characterised by progressive deple-
tion of  not only naive and memory CD4+ T cell sub-sets, 
but also the naive subset of  CD8+ T cells from peripheral 
blood, lymphoid organs and mucosal tissues leading to 
immunodeficiency5,6. On the other hand, TB leads to in-
creased immune activation, loss of  both naive and MTB 
specific CD4+ T cells by apoptosis and defective cytokine 
production7,8,9. Although TB treatment alone has shown 
no significant changes in viral load, CD4+ and CD8+ T 
cell sub-sets, ART causes reduction in viral load and im-
mune activation, restoration of  naive T cells in HIV/TB 
patients10,11,12.
 
Much as interrupting ART in HIV/TB patients has its 
benefits like relief  from tablet burden, reduction in costs 
and side effects of  drugs on the patient, it poses risks such 
as emergence of  drug resistance, resumption of  HIV-in-
duced immune suppression and chronic inflammation 
that may be detrimental13,14. The effect of  interrupted 
ART on the reconstitution of  naive and memory T cells 
during TB treatment in HIV/TB patients is not well un-
derstood. Other studies have reported that interrupted 
ART was as effective as continuous ART15. Therefore, in 
this report, we were answering a question of  whether in-
terruption of  ART regimen during HIV/TB co-infection 
distorts the balance of  naive and memory T cell recon-
stitution.To answer this question, HIV infected Ugan-
dan adults with active pulmonary TB with CD4 > 350 
cells/ml at baseline,3,6 and 12 months were examined. 
These participants were part of  randomised controlled 
clinical trial and were treated with both a combination of  
TB treatment and a 6-month punctuated course of  ART 
(n=39) or TB treatment alone (n=37). Using flow cytom-
etry, we measured changes in naive, memory and effector 
markers on T cells during the 6 months while ART was 




This is a very important study which was nested in a 
larger phase 3 clinical randomised study entitled “ Ran-
domised Clinical Trial of   6 month punctuated course of  
antiretroviral Therapy (PART)- ClinicalTrials.gov iden-
tifier:NCT007847 . Participants were Ugandan HIV+ 
adults with active pulmonary TB and CD4 > 350cells/
µL. In the current study, the authors sought to establish 
“the effect of  interrupted anti-retroviral treatment on the 
reconstitution of  memory and naive T cells during tuber-
culosis treatment in HIV patients with active pulmonary 
tuberculosis”.  It is very well written with no major ethical 
issues. 
In the large study, participants who were HIV positive 
with active pulmonary TB were recruited. The partici-
pants were randomised to receive 6 months of  TB treat-
ment alone in one treatment arm and the other treatment 
arm had 6 months of  both ART and TB treatment. Partic-
ipants aged between 18 and 60 years were recruited from 
Uganda-Case Western Reserve University Research Col-
laboration (UCWRU) within Mulago Hospital Complex 
in Kampala, Uganda and were followed for one year. Par-
ticipants with HIV-1 infection and ART naive with CD4 
count > 350cells/mm3 were eligible to participate in the 
study. Active pulmonary TB was confirmed with positive 
smear and /or culture results and HIV-1 was diagnosed 
by ELISA plus Western blot and confirmed with HIV 
RNA copy levels. Before enrolment participants signed 
informed consent. The study protocol was approved by 
the institution Review Board of  Case Western Reserve 
University/University Hospitals, University of  California 
at San Francisco, the Uganda National Council for Sci-
ence and Technology and Joint Clinical Research Centre 
in Kampala, Uganda.
 
In the large clinical trial, two weeks after study enrolment, 
participants were randomised to receive either 6 months 
of  standard tuberculosis treatment alone (treatment arm 
1) or tuberculosis treatment plus a punctuated course 
of  6 months of  ART (treatment arm 2) which included 
trizivir, and a combination of  lamivudine, abacavir and 
zidovudine. For TB therapy, participants were initially 
treated with a standard regimen of  directly observed TB 
therapy which involved two months of  rifampin, etham-
butol, isoniazid and pyrazinamide and then followed with 
four months of  isoniazid and rifampin. Cotrimoxazole 
was provided daily to participants after they had complet-
ed 2 months of  TB therapy or HIV-TB therapy.
 
Measurements
Demographic and clinical data
Demographic data and clinical symptoms of  tuberculosis 
were collected on standard forms. Participants then had 
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a physical exam, baseline chest radiograph and sputum 
samples were collected for a smear microscopy and cul-
ture at enrolment.  At two  and  five months after initia-
tion of  tuberculosis treatment, other sputum samples for 
Acid Fast Bacilli(AFB) smear and culture were obtained. 
The HIV-1 infection was diagnosed by means of  ELI-
SA and Western blot test and confirmed with HIV RNA 
copy levels.
Flow cytometric analysis of  markers of  memory, na-
ive and effector T cell populations
Immunophenotyping was performed. For flow cytom-
etry the following antibodies were used in two panels: 
the first panel included anti-CD4 allophycocyananin 
(APC), anti-CD62L phycoerythrin Cy5 (PE Cy5), and an-
ti-CD45RO fluorescein isothiocyanate (FITC), the second 
panel had anti-CD8 APC, anti-CD62L phycoerythrin Cy5 
(PE Cy5), and anti-CD45RO fluorescein isothiocyanate 
(FITC).  Mouse monoclonal isotypic control conjugated 
with PE, PE Cy5, FITC, and APC were used to deter-
mine non-specific binding and to set gating boundaries. 
All antibodies were obtained from Becton Dickson (BD) 
Pharmingen. Cells were acquired by a FACS Calibur flow 
cytometer (BD Bioscience) using Cellquest software (BD 
Bioscience) with further analysis performed using FlowJo 
Software (Tree Star, San Jose, CA). 25,000-50,000 cells 
were analyzed for each condition.  Lymphocytes were 
gated based on forward and side scatter characteristics 
and then CD4+ and CD8+ T cell populations determined. 
Then presence or absence of  CD45RO and CD62L were 
determined on CD4+ or CD8+ T cells (Figure 1). 
 
                                     Z 
Figure 1: How acquired flow cytometric data was analyzed to define naive, memory and 
effector markers on CD4+ and CD8+ T cells 
 
Analysis was done on dot plots using Flowjo programme as follows: Lymphocytes were gated on 
forward and side scatter (dot plot X).  The CD4+ Tcells were gated on lymphocytes (dot plot Y). 
Dot plot Z illustrates expression of CD45RO and CD62L on CD4+ T cells. Likewise the same 
was done on CD8+ T cells. These proportions were then used to define naive (CD45RO-
/CD62L+), memory (CD45RO+/CD62L+) and effector (CD45RO+/CD62L-) markers on CD4+ 
and CD8+ T cells. 
X Y
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Statistical considerations
Baseline characteristics plus comparison between treat-
ment arms were analysed using non-parametric unpaired 
t test. Changes in memory, naive and effector markers on 
CD4+ and CD8+ T cell subsets at 0, 3, 6 and 12 months 
within each treatment arm were evaluated using Wilcox-
on matched pairs test. This analysis was completed with 
Prism software version 4.0 (San Diego California USA). 
A p-value of  < 0.05 was considered to show statistical 
significance.
Results
Seventy six HIV-1 infected participants of  whom thirty 
nine received ART with concurrent TB treatment and 37 
received TB treatment alone, were analysed. Demograph-
ic baseline characteristics of  the two groups did not sig-
nificantly differ from each other (Table 1). 
The absolute CD4 T cell counts did not differ statistically 
between the different study visits within each treatment 
arm (Table 2).
Table 1: Demographic and baseline characteristics of study participants. 
Median values and interquartile ranges of  baseline characteristics were calculated. P values were 
calculated for the different variables between the groups. 
  
          Characteristic                            TB treatment alone          ART/TB treatment     
                                                                    n=37                          n=39                                  
                                                                                                                                 P               
Age median  (range) years 33 (19-54) 32  (23 - 49) .44 
Male sex (%)  24 (65)      23 (59) .98 
CD4 absolute cell count 
median  
(range) cells/ µL 
  
609.5 (374-1368) 532.5(283-1415) .31 
Viral load median (range) 
 log10 copies/ml 





Table 2: Absolute CD4 cell count analysis between the study visits in the two arms 
 
Study visit Tuberculosis treatment alone ART and Tuberculosis treatment 
Baseline 609.5  (374 – 1368)  532.5 (283 – 1415) 
6 months  527    (225 – 1331)  593    (348 – 2088) 
12 months  609    (209 – 1252)  527    (291 – 1207) 
  
*values in median (range) 
  
Punctuated ART combined with TB treatment alter 
CD8+ T cell subsets
Proportions of  naive (CD62L+/CD45RO-), memo-
ry (CD62L+/CD45RO+) and effector (CD45RO+/
CD62L-) CD8+  and CD4+ T cell subsets were measured 
at enrolment and every 3 months for a period of  one 
year. There was a significant increase of  naive CD8+ T 
cells during the 6 month period of  combined ART/TB 
treatment (p=0.003) and a significant decrease in effector 
CD8+ T cells (p=0.004, figure 2, graph B and D respec-
tively). However, when ART treatment was withdrawn, 
naive CD8+ T cells reduced significantly (p=0.02). Mem-
ory CD8+ T cell proportions remained relatively stable 
in both treatment arms. During 6 months, naive CD8+ T 
cell sub-sets increased significantly  among participants 
in ART-TB treatment arm than in the TB treatment arm 
(p=0.002, table 3). After completion of  6 months of  TB 
treatment, the naive CD8+ T cells increased significantly 
in the TB treatment alone arm (p=0.01, figure 2, graph 
A). During the first 3 months of  TB treatment in the 
TB treatment alone arm, effector CD8+ T cells decreased. 
Although this decrease was not significant, the next 3 
months of  TB treatment effector CD8+ T cells increased 
significantly to baseline levels (p=0.03, fig.2, graph C).




    
 
Figure 2: Changes in median of CD8+ cell subsets were measured in participants who received HIV-TB treatment  
(B & D)  and those on TB treatment alone (A & B). Percentage expression of naive (CD62+/CD45RO-; A, B), effector 
memory (CD62L+/CD45RO+; C, D) markers was analysed from baseline, 3, 6 and 12 months. Boxes indicate the 
interquartile ranges; whiskers indicate the highest and lowest values while the horizontal lines transecting  the 
boxes indicate the medians. Wilcoxon matched pairs test were performed to compare the median changes in 
these CD8+ T cell subsets within each treatment arm. 
CD4+ T cell subsets were not altered by combined 
HIV-TB treatment
There were no significant changes in the proportions of  
CD4+ T cell sub-sets in combined HIV-TB treatment as 
well as TB treatment alone throughout the 12 months of  
study. However, the naive CD4+ T cell sub-sets showed a 
trend towards increment in both arms but these changes 
were not significant (HIV-TB treatment: naive CD4+ T 
cell sub-sets, between baseline and 6 months p= 0.66; TB 
treatment alone: p=0.98, table 3).
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Discussion
In the majority of  chronically HIV-infected individuals 
left untreated, depletion of  CD4+ T cells, changes in dis-
tribution and function of  T cell sub-populations and al-
terations in CD4:CD8 T cell ratios are some of  the con-
sequences of  uncontrolled viral replication. This is made 
worse in HIV/TB co-infected patients with TB driving 
immune activation which enhances viral replication. 
Upon administration of  effective anti-retroviral therapy 
and TB treatment in HIV-TB patients, the peripheral T 
cells increase and alterations of  some T cell sub-popu-
lations occur16,17. In this prospective cohort study of  the 
effect of  interrupted ART on T cell sub-sets during treat-
ment of  active pulmonary tuberculosis among HIV in-
fected patients with CD4+ cell counts of  > 350 cells/µL, 
we observed that ART administered concurrently with 
TB treatment causes a significant increase in naive CD8+ 
T cells. The ART intervention increased the proportion 
of  naive CD8+ T cells during 6 months of  treatment and 
this proportion declined close to baseline values when 
ART was withdrawn. We also report that during the 6 
months of  intervention, the effector memory CD8+ T 
cells decreased significantly. In the TB treatment alone 
arm, after 6 months of  treatment, we observed a signifi-
cant increase in naive CD8+ T cells. T cell sub-population 
reconstitution has been a subject of  interest in HIV and 
TB infections for long time in research; however, most 
studies have been limited by focusing on either HIV or 
TB infection17,18,19. This study is one of  its kind that fo-
cuses on dual infections.
CD8+ T cells play an important role of  killing cells that 
harbour intracellular pathogens either through secreting 
cytokines like interferon gamma or production of  lysing 
biomolecules like granulysin/perforin. Loss of  naive T 
cells and skewing of  T cell sub-populations in HIV infec-
tion has been associated with rapid HIV disease progres-
sion18. In this study, the patients were in a less advanced 




                                                      CD8+                                               CD4+ 
T cell subset          
           TB 
  
     ART/TB 
  
  





Naive, %  (IQR) 
  
          
Baseline 22.0(15.5-35.0) 27.6(14.2-40.6) 48.0 (43.0-54.0) 45.0(35.6-58.5)   
3 months 26.9(21.0-36.5) 32.1(28.8 - 43.5) 49.0(40.5-55.0) 49.0(40.0-62.0)   
6 months 24.1α(15.3-33.1) 37.1α(26.1-57.2) 48.0(39.0-54.0) 48.5(37.0-60.5)   







































































            
  
Note: IQR; Interquartile Range 
Nonparametric unpaired t-test was used to compare changes between the two treatment arms. 
Wilcoxon matched pairs test was used to compare changes within each treatment arm. 
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stage of  HIV which provided the benefit of  rapid increase 
in the naive CD8+ T cell sub-population. This means that 
HIV and TB had not done tremendous damage to CD8+ 
stromal naive T cells to hinder their expansion. Tuber-
culosis is well known to rapidly increase HIV disease 
progression through facilitating T cell activation3,5,7.  Ad-
ditionally, T cell activation is known to be one of  the con-
tributing forces that hinders naive T cell regain and ex-
pansion. Several studies including this particular one have 
shown that tuberculosis treatment in HIV-TB patients 
reduces activation markers on CD4+ and CD8+ T cells in 
HIV patients co-infected with tuberculosis10,17,21. Chang-
es in homeostatic mechanisms and markers could have 
played a role of  reducing circulating numbers of  effector 
CD8+ T cells in the periphery to antigen reservoirs and 
primary sites of  infections. It could also suggest that ho-
meostatic micro-environment that is important in main-
tenance of  mature T cells had been partially damaged/or 
exhausted by HIV infection. Despite viral suppression to 
very low levels, it seems low levels of  HIV antigen pro-
duction persists in the tissue reservoirs. This is evident 
in that, the moment ART was withdrawn, naive CD8+ 
T cells fell to levels close to baseline. It is worthwhile to 
note that when naive CD8+ T cells reduced, there was no 
significant increase in the memory CD8+ T cell sub-popu-
lations. This could suggest that damage was already done 
to naive CD8+ T cell sub-population at an earliest stage 
of  uncontrolled HIV replication and their expansion was 
already impaired prior to initiation of  treatment. Then 
the importance of  early initiation of  ART on recovery of  
naive T cell pool remains to be seen. The sudden decrease 
at 3 months in effector CD8+ T cells seen TB treatment 
arm could be due to introduction of  treatment as seen 
elsewhere20.
 
It has been shown that ART improves restoration of  na-
ive CD4 T cell counts in HIV infected individuals9, 11,20. 
Some researchers demonstrate that TB treatment increas-
es CD4+ T cell counts in HIV-TB co-infected persons17 
while others show no change during therapy15.We report 
no significant changes in both absolute CD4+ counts and 
T cell sub-set proportions in both treatment arms. This 
observation has been supported by studies that have done 
proliferation experiments which have demonstrated that 
CD4+ proliferation is driven by CD4+ cell depletion and 
viral load while CD8+ cell proliferation is driven by viral 
load alone. Since these patients were at a less advanced 
stage (CD4 T cell counts >350cells/µL) of  disease pro-
gression, when ART was interrupted there were no sig-
nificant changes in naive, memory and effector CD4+ T 
cell proportions in HIV/TB treatment group.  This has 
also been noted in some studies there is limited influence 
on the magnitude of  change of  naive and memory CD4+ 
T sub-sets in asymptomatic compared to advanced stage 
of  disease18,20. In contrast to advanced HIV patients, pre-
vious studies have shown an early increase of  memory 
and late increase of  naive CD4+ cells while on ART20. 
This suggests that gradual increase of  these sub-sets is 
dependent on the pre-existing naive T cells in HIV in-
fected patients. If  this remains the case for HIV patients 
co-infected with TB remains a question to be answered.
Conclusion
Our analysis in this study provides more insight in the 
reconstitution of  T cell sub-populations in HIV-TB in-
fected patients with high CD4+ T cell counts. Although 
initially, this study was not designed with a systematic 
ART interruption model, interruption of  ART did not 
yield immunological benefits which suggest poor clinical 
outcomes to the patients.
One weak point of  this study is that there was no control 
group to compare with the percentages of  T cell sub-sets 
in the two treatment groups. For ethical reasons such a 
study would never be conducted. Further research needs 
to be performed in functional analysis of  these pheno-




We acknowledge and thank the staff  of  the Uganda-Case 
Western Reserve University Collaboration, the Mula-
go Tuberculosis clinic, the Joint Clinical Research Cen-
tre-Case Western Reserve University TB Microbiology 
and immunology laboratories and the Core Laboratory at 
the Infectious Disease Institute. We appreciate the con-
tributions towards this study by Mary Walusimbi, Mary 
Nsereko, Denise Johnson, Alphose Okwera, Ezekiel Mu-
pere, Keith Chervenak, Pierre Peters, Alice Turyamuree-
ba, Paul Mubiri. We are grateful to the patients who par-
ticipated in this study.
Trial Registration. Clinicaltrial.gov NCT007847
960African Health Sciences Vol 17 Issue 4, December, 2017
Conflict of  interest
There was no conflict of  interest.
References
1. Harries AD, Hargreaves NJ, Chimzizi R and Salaniponi 
FM. Highly active antiretroviral therapy and tuberculo-
sis control in Africa: Synergies and potential.  Bulletin of  
the World Health Organisation 2002; 80: 464-469. PM-
CID:PMC2567537.
2. Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom 
DL, Nelson LM, et al. Impact of  pulmonary tubercu-
losis on survival of  HIV-infected adults: a prospective 
epidemiology study in Uganda. AIDS 2000; 14: 1219-28 
PubMed . PMID:10894287.
3. Zahra Toosi. Virological and Immunological im-
pact of  tuberculosis on human immunodeficiency virus 
type 1. The Journal of  Infectious Disease 2003;188: 1146-55.
DOI:https://doi.org/10.1086/378676
4.      WHO. Global Tuberculosis control report 2011. Wh-
qlibdoc.who.int/publications/2011/9789241564380_
eng.pdf
5. Barton F, Haynes, Pantaleo G, Fauci AS. Toward an 
understanding of  the correlates of  pro-active immu-
nity to HIV infection. Science 1996; 271: 324-8 PubMed 
.DOI:10.1126/science.271.5247.324
6.  Levy JA. HIV pathogenesis and long term survival. 
AIDS 1993; 7:140-10 PubMed .  PMID: 8280406
7. Hirsch CS, Toosi Z, Vanham G, Johnson JL, Peters P, 
Okwera A, et al. Apoptosis and T cell hypo-responsive-
ness in pulmonary tuberculosis. Journal of  infectious Diseases 
1999; 179: 945-53. DOI: https://doi.org/10.1086/314667
8.  Rodrigues DSS, Medeiros EAS, Weckx LY, Bonnez 
W, Salomao R, Kallas EG. Immunophenotypic charac-
terization of  peripheral T lymphocytes in Mycobacteri-
um tuberculosis infection and disease. Blackwell Science 
Ltd. Clinical Experimental Immunology. 2002; 128: 149-154. 
DOI:10.1046/j.1365-2249.2002.01809.x
9.  Bohler T, Walcher J, Holzl-Wenig G, Geiss M, Bu-
chholz B, Linde R, Debatin KM. Early effects of  an-
tiretroviral combination therapy on activation, apoptosis 
and regeneration of  T cells in HIV-1 infected children 
and adolescents. AIDS. 1999; 13(7):779-89. PubMed 
PMID:10357376.
10.  Mahan CS, Walusimbi M, Johnson DF, Lancioni C, 
Baseke J, Chervenak KA, et al. Tuberculosis Treatment in 
HIV Infected Ugandans with CD4 Counts >350 cells/
mm3 Reduces immune Activation with no effect on 
HIV Load or CD4 count. PloS ONE 2010; 5 (2) e9138. 
PubMed  DOI:10.1371/journal.pone.0009138.
11.  Plana M, Garcia F, Gallart T, Tortajada C, Soriano A, 
Plalou E, et al. Immunological benefits of  anti-retrovi-
ral therapy in very early stages of  asymptomatic chronic 
HIV-1 infection. AIDS 2000; 8:14(13): 1921-33. PubMed 
PMID:10997396
12.  Lane HC. Pathogenesis of  HIV infection: Total 
CD4+ T cell pool, Immune Activation and Inflammation. 
Topics in HIV Medicine 2010; 18 (1): 2-6.PMID:20305309.
13.  Metzner KJ, Leeman C, Di-Giallonardo F, Grube 
C, Scherrer AU, Braun D, Kuster H, et al. Reappearance 
of  Minority K103N HIV-1 Variants after interruption 
of  ART Initiated during Primary HIV-1 Infection. PloS 
ONE 2011; 6(7):  e21734. PubMed DOI:10.1371/jour-
nal.pone.0021734
14.  Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwi-
ine D, Mbamanya F, et al. A Randomised, controlled, Trial 
of  Short Cycle Intermittent Compared to ContinousAn-
tiretroviral therapy for the Treatment of  HIV infection in 
Uganda. PloS ONE 2010; 5(4): e10307. DOI: https://doi.
org/10.1371/journal.pone.0010307.
15.  Morris L, Martin DJ, Bredell H, Nyok SN, Sacks L, Pen-
dle S, et al. Human immunodeficiency virus-1 RNA levels 
and CD4 lymphocyte counts, during treatment for active 
tuberculosis, in South African patients. Journal of  Infectious 
Diseases 2003; 187: 1967-1971. DOI:10.1086/375346
16.  Gregory K Robbins, John G Spritzler, Ellen S Chan, 
David M Asmuth, Rajesh TG, Benigno A Rodriguez, et 
al. Incomplete Reconstitution of  T cell sub-sets on com-
bination Ant-iretroviral Therapy in the AIDS Clinical Tri-
als Group Protocol384.  Clinical Infectious Diseases. 2009; 
48(3): 350-361. DOI:10.1086/595888
17.  Dean GL, Edwards SG, Ives NJ, et al. Treatment 
of  tuberculosis in HIV-infected persons in the era of  
highly active antiretroviral therapy. AIDS 2002; 16: 75-83 
PubMed . PMID: 11741165.
18.  Autran B, Carcelain G, Li TS, Blanc C, Mathez D, 
Tubiana R, et al. Positive effects of  combined antiretro-
viral Therapy on CD4+ T cell homeostasis and function 
in advanced HIV disease. Science 1997; 277:112. DOI: 
10.1126/science.277.5322.112
19.  Brinda Emu, Walter J Moretto, Rebecca Hoh, Mellisa 
961 African Health Sciences Vol 17 Issue 4, December, 2017
Krone, Jeffrey N Martin, Douglas F Nixon, et al. Compo-
sition and function of   T cell sub-populations are slow to 
change despite effective antiretroviral treatment of  HIV 
Disease. PloS ONE 2014; 9(1):  e85613. PubMed DOI: 
10.1371/journal.pone.0085613
20.  Cecilia Tortajada, Felipe Garcia, Montserrat Plana, 
Teresa Gallart, Maria Jose Maleno, Jose Maria Miro, Jose 
Maria Gatell. Comparison of  T –cell subsets’ reconstitu-
tion after 12 months of  highly active antiretroviral ther-
apy initiated during early versus advanced states of  HIV 
disease.  Journal of  Acquired Immune Deficiency Syndromes. 
2000; 25:296-305. PMID:11114829.
21. Christina L Lancioni, C Scott Mahan, Denise F John-
son, Maria Walusimbi, Keith A Chervenak, Sophie Na-
lukwago, et al. Effects of  Anti-retroviral Therapy on im-
mune Function of  HIV-infected Adults with Pulmonary 
Tuberculosis and CD4+ >350 Cells/mm3. Journal of  In-
fectious Diseases 2011; 203: 992-1001.DOI:10.1093/infdis/
jiq141
962African Health Sciences Vol 17 Issue 4, December, 2017
